CNS monoclonal antibody therapies demand rigorous screening and monitoring to ensure patient safety in MS, NMOSD, and Alzheimer disease.
Bill Holt
Advertisement
Bill Holt, DO, is vice president, Neuroscience Therapeutic Area, at ICON.
Articles by Bill Holt
Advertisement
Latest Updated Articles
Advertisement
Advertisement